Olitigaltin is under clinical development by Galecto and currently in Phase III for Idiopathic Pulmonary Fibrosis. According to GlobalData, Phase III drugs for Idiopathic Pulmonary Fibrosis have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Olitigaltin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Olitigaltin (GB-0139) is under development for the treatment of idiopathic pulmonary fibrosis and coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is formulated as an inhalable powder via dry powder inhaler. It acts by targeting galectin-3.
Galecto is a drug development company. It focuses on the development of galectin modulators for the treatment of cancer, fibrosis and inflammation. The company develops activators and inhibitors of galectins. Its pipeline products include GB0139 to treat
For a complete picture of Olitigaltin’s drug-specific PTSR and LoA scores, buy the report here.